The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

1251 AVENUE OF THE AMERICAS, NEW YORK, NY 10020-1104, USA
Tel:
Work +1 212 335 4500
Fax:
Fax +1 212 335 4501
Web:
www.dlapiper.com

Stuart Pollack

Tel:
Work 1 212 335 4964
Email:
DLA Piper LLP (US)

Work Department

Patent Litigation

Position

Partner

Career

Dr. Stuart Pollack concentrates his practice on patent litigation as well as patent prosecution and patent counseling and opinion work.

 

With extensive trial experience in federal court, Dr. Pollack has helped obtain favorable judgments in several suits on behalf of pioneer drug companies, including suits brought under the Hatch-Waxman Act against potential generic entrants. His work has focused on pharmaceutical products and drug substances, polymers, optics and chemical reactors, and he has also worked on cases involving mechanical inventions.

 

Dr. Pollack has successfully represented companies in suits at the International Trade Commission. He has also helped obtain patents for his clients in pharmaceutical and chemical technology at the Patent and Trademark Office.

Education

JD, Columbia University School of Law; PhD, Northwestern University; MS, Northwestern University; BA, University of Rochester


United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

DLA Piper LLP (US)’s ‘excellent, responsive and knowledgeable’ department has considerable experience assisting high-profile clients with regulatory, transactional and IP matters, as well as complex global disputes. San Diego-based co-head Lisa Haile and New York-based Stuart Pollack have been leading advice to SteadyMed on various patent invalidation claims brought against United Therapeutics before the Patent Trial and Appeal Board (PTAB). Co-head Richard Mulloy and Drew Wintringham, who are in San Diego and New York, respectively, have been representing Covidien in patent litigation brought against Ethicon arising from the release of Ethicon’s Enseal X1 medical device. The team also acted for Sanpower Group on its $820m acquisition of Dendreon Pharmaceuticals. Also led by product liability expert Matthew Holian in Boston, the team includes George Karavetsos in Miami, Loren Brown in New York, Raymond Williams in Philadelphia, Larry Nishnick in San Diego and Aaron Fountain, who splits his time between Austin and Houston.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to